SynAct Pharma
Developing oral resolution therapies for inflammatory diseases like rheumatoid arthritis.
SYNACT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008241491 (+1 more)
- LEI:
- 549300RRYIEFEQ72N546
- Country:
- Sweden
- Address:
- Scheelevägen 2, 223 63 Lund
- Website:
- https://synactpharma.com/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
SynAct Pharma is a clinical-stage biotechnology company focused on developing innovative medicines for inflammatory diseases. The company's core strategy centers on resolution therapy, an approach that aims to resolve, rather than inhibit, inflammatory processes by restoring the body's natural immune balance. Its lead candidate, resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development pipeline targets a wide spectrum of acute and chronic inflammatory conditions, such as rheumatoid arthritis, with the goal of reducing disease progression and offering a better-tolerated treatment alternative to establish a new standard of care.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SynAct Pharma and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-16 08:45 |
Board/Management Information
SynAct Pharma’s CFO Björn Westberg leaves for new leading position
|
English | 53.7 KB | |
| 2025-09-16 08:45 |
Board/Management Information
SynAct Pharmas CFO Björn Westberg slutar för ny ledande befattning
|
Swedish | 53.4 KB | |
| 2025-08-29 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
|
Swedish | 58.9 KB | |
| 2025-08-29 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in SynAct Pharma AB
|
English | 58.9 KB | |
| 2025-08-20 07:30 |
Interim Report
|
Swedish | 6.6 MB | |
| 2025-08-20 07:30 |
Interim Report
|
English | 6.6 MB | |
| 2025-08-15 08:55 |
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter en andra konvertering av teckningsoptioner
|
Swedish | 62.1 KB | |
| 2025-08-15 08:55 |
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after second conversion of warrants
|
English | 61.3 KB | |
| 2025-08-05 11:34 |
Major Shareholding Notification
|
Swedish | 10.6 KB | |
| 2025-07-31 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
|
Swedish | 59.6 KB | |
| 2025-07-31 18:00 |
Share Issue/Capital Change
Change in number of shares and votes in SynAct Pharma AB
|
English | 59.3 KB | |
| 2025-07-15 22:13 |
Share Issue/Capital Change
Correction: SynAct to receive SEK 17.7 million after conversion of warrants
|
English | 61.8 KB | |
| 2025-07-15 22:13 |
Share Issue/Capital Change
Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
|
Swedish | 62.8 KB | |
| 2025-07-15 21:00 |
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
|
Swedish | 62.2 KB | |
| 2025-07-15 21:00 |
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after conversion of warrants
|
English | 61.3 KB |
Automate Your Workflow. Get a real-time feed of all SynAct Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SynAct Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-30 | Anders Kronborg | Other | Buy | 28,902 | 250,002.30 SEK |
| 2024-06-01 | Björn Westberg | Other | Other | 516,205 | N/A |
| 2024-04-30 | Jeppe Øvlesen | Other | Other | 58,139 | 499,995.40 SEK |
| 2024-04-30 | Anders Kronborg | Other | Other | 34,883 | 299,993.80 SEK |
| 2024-03-21 | Jeppe Øvlesen | Other | Other | 245,870 | 1,696,503.00 SEK |
| 2023-11-09 | Thomas Jonassen | Other | Other | 3,531,644 | 22,072,775.00 SEK |
| 2023-11-09 | Thomas Jonass | Other | Other | 2,161,225 | 13,507,656.25 SEK |
| 2023-01-16 | Jeppe Øvlesen | Other | Other | 1,161,777 | 72,727,240.20 SEK |
| 2023-01-16 | James Knight | Other | Other | 77,452 | 4,848,495.20 SEK |
| 2023-01-16 | Thomas Boesen | Other | Other | 32,917 | 2,060,604.20 SEK |
